These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 15308790)
1. The unifying role of matrix metalloproteinases in atheroma and vascular stroke. Tayebjee MH; Lip GY; MacFadyen RJ Stroke; 2004 Oct; 35(10):2239. PubMed ID: 15308790 [No Abstract] [Full Text] [Related]
2. Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability. Smeglin A; Frishman WH Cardiol Rev; 2004; 12(3):141-50. PubMed ID: 15078583 [TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Visse R; Nagase H Circ Res; 2003 May; 92(8):827-39. PubMed ID: 12730128 [TBL] [Abstract][Full Text] [Related]
4. Role of matrix metalloproteinases in normal and disease processes. McDonnell S; Morgan M; Lynch C Biochem Soc Trans; 1999 Aug; 27(4):734-40. PubMed ID: 10917674 [No Abstract] [Full Text] [Related]
5. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Lorenzl S; De Pasquale G; Segal AZ; Beal MF Stroke; 2003 Jun; 34(6):e37-8; author reply e37-8. PubMed ID: 12750528 [No Abstract] [Full Text] [Related]
6. Mucosal expression of matrix metalloproteinases and their tissue inhibitors in ulcerative colitis patients. Kusugami K; Nobata K; Tsuzuki T; Ando T; Ina K J Gastroenterol; 2003; 38(4):412-3. PubMed ID: 12743787 [No Abstract] [Full Text] [Related]
7. [Metalloproteinases and their inhibitors: the importance of extracellular matrix degradation in malignancy]. Sela B Harefuah; 2000 Dec; 139(11-12):446-51. PubMed ID: 11341192 [No Abstract] [Full Text] [Related]
8. [Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathogenesis of rheumatoid arthritis]. Fiedorczyk M; Klimiuk PA; Sierakowski S; Kita K Pol Merkur Lekarski; 2006 Feb; 20(116):228-31. PubMed ID: 16708647 [TBL] [Abstract][Full Text] [Related]
9. [The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in invasion of tumours of neuroepithelial tissue]. Bogaczewicz J; Jasielski P; Mosiewicz A; Trojanowski T; Suchozebrska-Jesionek D; Stryjecka-Zimmer M Neurol Neurochir Pol; 2006; 40(5):404-12. PubMed ID: 17103354 [TBL] [Abstract][Full Text] [Related]
10. [Roles of matrix metalloproteinases and tissue specific inhibitors of metalloproteinases in dentinogenic ghost cell tumor and ghost cell odontogenic carcinoma]. Geng N; Ban Y; Chen Y; Yang MZ; Bao DM; Yi XZ Zhonghua Kou Qiang Yi Xue Za Zhi; 2008 Dec; 43(12):756-60. PubMed ID: 19134356 [TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and their regulators are cardiovascular therapeutic targets. Luft FC J Mol Med (Berl); 2004 Dec; 82(12):781-3. PubMed ID: 15551107 [No Abstract] [Full Text] [Related]
12. Matrix metalloproteases: a role in overuse tendinopathies. Magra M; Maffulli N Br J Sports Med; 2005 Nov; 39(11):789-91. PubMed ID: 16244185 [No Abstract] [Full Text] [Related]
13. [Matrix metalloproteinases and their tissue inhibitors]. Trojanek J Postepy Biochem; 2012; 58(3):353-62. PubMed ID: 23373420 [TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. Bhalla V; Georgiopoulou VV; Azeem AA; Marti CN; Cole RT; Laskar SR; De Staercke C; Hooper WC; Smith AL; Kalogeropoulos AP; Butler J Int J Cardiol; 2011 Sep; 151(2):237-9. PubMed ID: 21723628 [No Abstract] [Full Text] [Related]
15. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability. Xie S; Nie R; Wang J J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879 [TBL] [Abstract][Full Text] [Related]